Latest Conference Coverage

Enhanced Dosing of Donanemab Lowers ARIA Risk, Anti-Tau Agent E2814 Shows Promising Results, Combination Approach of Intranasal Insulin and Empagliflozin

Neurology News Network. for the week ending November 2, 2024. [WATCH TIME: 4 minutes]

The Promise of Cannabinoid Therapy for Agitation in Advanced Alzheimer Disease: Brent Forester, MD, MSc

The chair of psychiatry at Tufts University School of Medicine talked about a recent study that suggested synthetic tetrahydrocannabinol could reduce agitation in patients with advanced Alzheimer disease. [WATCH TIME: 5 minutes]

Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD

The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]

Episode 127: Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lawrence Robinson, MD. [LISTEN TIME: 15 minutes]

Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent Increase in APOE2 Expression

LX1001, an AAV gene therapy, was considered safe and well tolerated, with no events of amyloid-related imaging abnormalities (ARIA) observed.

Refining Alzheimer Treatment Through Biomarker-Based Patient Selection: Michael Woodward, MD, FRACP; Anthony Caggiano, MD, PhD

The head of dementia research at Austin Health and the chief medical officer at Cognition Therapeutics talked about recently presented phase 2 findings on CT1812, an investigational medicine for patients with mild to moderate Alzheimer disease, at CTAD 2024. [WATCH TIME: 5 minutes]

Screening Experience of Phase 2 Autonomy Study Provides Insights for Anti-Tau Trials in Alzheimer Disease

In total, more than half of the screened population failed by not meeting plasma p-tau217 criteria and of the remaining, most participants were not in the intermediate tau PET range.

The Role of Monoclonal Antibodies and Emerging Combination Treatments to Expand Alzheimer Therapeutics: Howard Fillit, MD

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation talked about how Alzheimer disease treatment may evolve through combination therapies, adding potential anti-tau and anti-inflammatory agents to improve patient outcomes. [WATCH TIME: 5 minutes]

Intranasal Insulin and Empagliflozin Demonstrate Therapeutic Potential as Combination Treatment for Alzheimer Disease

Insulin treatment significantly increased beneficial plasma biomarkers, including SNAP25, SMOC1, BDNF, and VCAM1.

Using Biomarker Testing to Advance Alzheimer Diagnostics: Margherita Carboni, PhD

The indication lead of neurology at Roche Diagnostics International talked about the latest Alzheimer biomarkers that are aimed to transform diagnostic accuracy and accessibility as well as enhance early detection and treatment. [WATCH TIME: 5 minutes]

Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PharmD, MPH, CPHQ

The rare disease population health strategy lead at UCB provided clinical insight on some of the unique challenges of diagnosing myasthenia gravis, and some of the early signs clinicians and non-specialists should look out for. [WATCH TIME: 3 minutes]

Phase 3 TRAILRUNNER-ALZ 3 to Test Effects of IgG1 Monoclonal Antibody Remternetug in Early Alzheimer Disease

The multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven trial will use time to clinical progression, defined as an increase in Clinical Dementia Rating score, as the primary end point.

Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]

Advancing Alzheimer Treatment Through Gamma Oscillation Stimulation: Ralph Kern, MD, MHSc

The chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]

Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery

Compared with the standard dosing arm, those on an enhanced titration dosing of donanemab demonstrated a 41% reduction in the relative risk of ARIA-E.

Anti-Tau Agent E2814 Shows Impact on Early and Late Tau Biomarkers, Further Supporting Development

Despite a small cohort sample size, treated patients with E2814 demonstrated significant reductions in p-tau217 after 12 weeks of treatment, sustained through the 108-week time point.

AAV Vectors in Gene Therapy: Overcoming Barriers for Muscular Dystrophy Treatment

The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP

Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases.

Investigational Nipocalimab Demonstrates Efficacy and Safety in Adolescent Population of Myasthenia Gravis

In a small sample population of adolescents with myasthenia gravis, nipocalimab met its primary end point, showing a significant reduction in total serum immunoglobuin over a 24-week period.

Future Plans and Clinical Promise of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

The director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes]

How Vidofludimus Calcium Addresses Unmet Treatment Needs in Multiple Sclerosis: Andreas Muehler, MD, MBA

The chief medical officer at Immunic provided clinical insight on the dual mechanism of action of vidofludimus calcium, and how its positioned as a treatment option across all MS subtypes. [WATCH TIME: 3 minutes]

The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial

David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease.

Challenges and Opportunities of Adapting Medical Education in a Digital Age: Lawrence Robinson, MD

The senior scientist at Sunnybrook Research Institute talked about both the opportunities and challenges with the shift of technological advancement in medical education, especially in fostering critical thinking and managing the vast influx of information. [WATCH TIME: 4 minutes]

NeuroVoices: Lawrence Robinson, MD, on Innovating Educational Approaches for Neuromuscular Specialists

The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on his lecture given at AANEM 2024, focusing on the challenges and opportunities of teaching the next generation of practitioners.

Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment

The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.

Understanding Nipocalimab’s Impact on Myasthenia Gravis Using MG-ADL

Constantine Farmakidis, MD, an associate professor of neurology at the University of Kansas Medical Center, provided clinical commentary on a subanalysis of a phase 3 study assessing nipocalimab, an investigational agent, in generalized myasthenia gravis.

Details Behind the Phase 3 MyClad Study of Cladribine in Myasthenia Gravis

Study investigator Henry Kaminski, MD, provided clinical insight on a unique trial assessing the efficacy and safety of oral cladribine tablets, an FDA-approved medication for multiple sclerosis, in patients with myasthenia gravis.

Subcutaneous Efgartigimod PH20 Efficacious in Patients With CIDP Previously Treated

A recent analysis of the phase 3 ADHERE trial demonstrated the clinical benefit of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy.

Clinical Insights From Phase 3 VIVACITY-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis

Tuan Vu, MD, a professor of neurology at the University of South Florida, provided brief commentary on topline data of the phase 3 VIVACITY-MG3 study presented at AANEM 2024.

Phase 3 Trial to Assess Therapeutic Effect of IV Efgartigimod in Seronegative Myasthenia Gravis

The phase 3 study is expected to include 110 patients with seronegative myasthenia gravis who will be randomly assigned to IV efgartigimod or placebo for a 5-week follow-up, followed by an open-label extension.